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Abstract
Aims/hypothesis Type 1 diabetes complicated by hypoglycaemia
is prevalent in socioeconomically deprived populations.
Islet transplantation is of proven efficacy in type 1 diabetes
complicated by hypoglycaemia, but it is not known if nationally
funded programmes reach the socioeconomically deprived.
Our aim was to determine: (1) socioeconomic indices in
participants referred to our nationally funded programme; and
(2) if metabolic outcomes in our transplant recipients were
improved.
Methods Participants referred (n=106) and receiving trans-
plants (n=18; 32 infusions) were examined with respect to
socioeconomic status (deprivation category score) and their
ability to work and drive. In participants followed for
≥12 months after transplantation, metabolic and anthropomet-
ric measurements (n=14) were recorded pre- and post-
transplant (assessed ~1, ~3, ~6 and ~12 months with mixed-
meal tolerance tests and 6 day continuous glucose monitoring
assessments). Donor data was also examined.
Results There was a greater prevalence of socioeconomic
deprivation in referred and transplant recipients than the gen-
eral population (p<0.05). Of the transplant recipients, 73%
were socioeconomically deprived, 88% did not hold a driver’s
license and 94% had reduced ability to work (all p<0.01 vs
referred participants). Donors were predominantly obese and
included circulatory death donors. At 12 months, 93% of par-
ticipants who had received transplants had graft function, di-
minished frequency of hypoglycaemia (10 [4–11] vs 0 [0–2]
hypoglycaemic episodes/week), improved awareness of
hypoglycaemia (Gold score 7 [5–7] vs 1 [1–2]) and glycaemic
control (HbA1c: 7.9% [7.2–8.5%]; 63 [55–69] mmol/mol vs
7.2% [6.8–7.5%]; 55 [51–58] mmol/mol), diminished
glycaemic lability and decreased central adiposity (all p<0.05).
Conclusions/interpretation A nationally funded islet trans-
plant programme reaches the socioeconomically deprived
and outcomes are significantly improved in this group.
Keywords Hypoglycaemia . Impaired awareness of
hypoglycaemia . Islet transplantation . Socioeconomic
deprivation
Abbreviations
CGMS Continuous glucose monitoring systems
DBD Donation after brain death
DCD Donation after cardiac death
DEPCAT Deprivation category
DVLA Driver and Vehicle Licensing Agency
IAH Impaired awareness of hypoglycaemia
IEQ Islet equivalents
IQR Interquartile range
MM Mismatch
MMTT Mixed-meal tolerance test
UKITC UK Islet Transplant Consortium
VPT Vibration perception threshold
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Introduction
Type 1 diabetes is characterised by destruction of pancreatic
beta cells by autoimmune processes leading to an absolute
requirement for insulin replacement. Hypoglycaemia is the
most common side effect of insulin treatment, with severe
hypoglycaemia affecting approximately 25% of patients with
type 1 diabetes [1, 2], and is associated with increased mor-
bidity and mortality [3, 4]. Repeated episodes of
hypoglycaemia are associated with hyperinsulinemia and di-
minished counterregulatory responses [5, 6], leading to im-
paired awareness of hypoglycaemia (IAH) [2].
Although there may be an improvement in awareness of
severe hypoglycaemia by the avoidance of low blood glucose
levels [7, 8], in practice this is difficult to achieve [9]. Alloge-
neic islet transplantation offers a minimally invasive option for
beta cell replacement in people with type 1 diabetes compli-
cated by recurrent severe hypoglycaemia and/or marked
glycaemic lability [10], and results in improved awareness of
hypoglycaemia [11]. In 2000, the Edmonton protocol for islet
transplantation achieved insulin independence in seven con-
secutive individuals who received high numbers of purified
islets under steroid-free immunosuppressive regimens [12].
An integrated UK Islet Transplant Consortium (UKITC)
with a commissioned service for Scotland was established
between 2008 and 2009 [13]. The consortium was fully
funded by the National Health Service and freely available
at the point of care. Islet transplantation was endorsed by the
National Institute for Health and Care Excellence, with the
aim of preventing recurrent severe hypoglycaemia (6),
attaining an HbA1c level <7% (<53 mmol/mol), reducing ex-
ogenous insulin requirements and quantifying graft function
by C-peptide secretion [14]. Achievement of insulin indepen-
dence was not a primary goal [10]. There is evidence that
patients with type 1 diabetes who are socioeconomically de-
prived have the greatest problems with hypoglycaemia [15],
but the degree to which nationally funded services receive
referrals or perform transplants in individuals from such
groups is not known.
A shared national vascularised pancreas and islet transplant
donor allocation scheme exists in the UK. Donor pancreases
are equally distributed between solid organ and islet recipi-
ents, and pancreases from donors with a high BMI are prefer-
entially offered for use in islet transplantation. The aim of islet
transplantation is to achieve a total of ≥10,000 islet equiva-
lents (IEQ)/kg recipient weight within 12 months of the first
transplant, including the routine use of islets from donation
after cardiac death (DCD).
Our aim was to determine the socioeconomic and demo-
graphic indices of patients referred to, and receiving islet
transplants in, our nationally funded programme [16] and to
evaluate the metabolic outcomes of patients receiving islet
transplants at our single UK centre [17].
Methods
Organ donors, islet isolation and transplantation procedures
Donor data including sex, ethnicity, age, weight, height, BMI,
waist circumference, DCD vs donation after brain death
(DBD) status and ischaemic time were recorded. Following
digestion with Liberase (Roche, Basel, Switzerland), islets
were purified, quality-assessed and product-released at a me-
dian time of 36 h from the Scottish National Islet Isolation
Laboratory [18] with minimum release criteria [17]. IEQ
counts, purity and viability were documented. Islets were
transplanted by percutaneous transhepatic delivery into the
portal vein under radiological guidance, and recipients re-
ceived intravenous insulin and heparin infusions
perioperatively, followed by low molecular weight heparin
for 7 days [17]. All recipients received alemtuzumab 30 mg
subcutaneously preceding their first transplant and were main-
tained on tacrolimus (target level 7–9 μg/l) and mycopheno-
late mofetil, along with prophylactic trimethoprim/
sulfamethoxazole and valganciclovir (in the case of donor or
recipient cytomegalovirus positivity) for 6 months.
Referred participants
Participants were enrolled from November 2009 until May
2014 from our clinic. Detailed personal information (includ-
ing social and demographic data, employment status, driving
status, ethnicity and smoking status) was collected from all
referrals. The Deprivation Category (DEPCAT) score divides
postcode sectors into seven categories in relation to income,
employment, health, housing and education and is a robust
measure of socioeconomic status [19]. People with DEPCAT
scores of 4–7 have been classified as being socioeconomically
deprived [19]. DEPCATscores for the 5.06 million population
in Scotland were derived from the 2001 census [19], and the
national prevalence of socioeconomic deprivation was com-
pared with data from referred and transplanted participants.
The employment status of the participants was compared with
the national figures from the Scottish Household Survey [20].
In the UK, stringent driving regulations exist and individuals
with severe hypoglycaemia requiring assistance must declare
this to the Driver and Vehicle Licensing Agency (DVLA) and
cannot re-apply for their license until 12 months have passed
since their penultimate hypoglycaemic event [21, 22]. The
proportion of people with a driver’s license in the general
population was derived from government statistics [23] and
compared with data from our participants.
Islet transplant recipients
All participants had C-peptide-negative diabetes complicated
by recurrent severe hypoglycaemia (≥1 event over the
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preceding 12 months that required assistance) despite
optimised conventional management. All except one partici-
pant received transplants for severe IAH; one participant with
normal renal function received a transplant for glycaemic var-
iability with progressive complications from diabetic retinop-
athy. Severe insulin resistance (insulin requirements
>0.7 units/kg with daily dose insulin >60 units and HbA1c
level <9.0% [75 mmol/mol]) was an absolute contraindication
and obesity a relative contraindication for islet transplantation.
There were no contraindications to immunosuppressive therapy
and renal function was not impaired (GFR >60 ml/min/1.73 m2
and albumin excretion rate <300 mg/24 h).
Participants eligible for transplants were listed on the UK
Organ Donation and Transplant waiting list after HLA typing
and unacceptable HLA antigen definition to avoid immuno-
logically incompatible transplantation. All islet transplant re-
cipients underwent the following assessments at each visit.
Assessment visits Participants were assessed pre-transplant
(anthropometric measurements were made on the ward prior
to transplant) and then at approximately 1, 3, 6 and 12 months
after first transplant as per UKITC protocols. All assessments
except the 3 month assessment were made within 1 week
before or after the intended time point; at 3 months, the medi-
an (interquartile range [IQR]) time was 3.6 (3.3–3.5) months
post-transplant by which time eight of the 14 participants had
received a second transplant. At the first visit, detailed person-
al histories were taken and at all visits diabetes control,
hypoglycaemia measures, caloric assessments and anthro-
pometry were assessed as outlined below.
Diabetes assessments, hypoglycaemia measures and food
diaries Duration of diabetes was calculated at the time of
the first islet transplant. Information about insulin therapy,
awareness of hypoglycaemia (Gold Score and Clarke Scores
≥4, reflecting IAH) and frequency of severe hypoglycaemia
pre-transplant and prospectively post-transplant (over the pre-
ceding 1 week period) was collected at all visits.
Hypoglycaemia was recorded as a plasma glucose concentra-
tion <4 mmol/l [24, 25]. Continuous glucose monitoring sys-
tems (CGMS) (iPro2; Medtronic, Northridge, CA, USA )
were used to gain 6 day glycaemic profiles. Over this period,
self-reported food diaries were completed.
Complications from diabetes were recorded at baseline,
including a history of previous diabetic retinopathy [26], using
the Scottish Care Information–Diabetes Collaboration data-
base and hospital records. A history of autonomic neuropathy
was diagnosed from investigations and/or from the clinical
history, and peripheral neuropathy was measured using a
neurothesiometer (Euroenergy, Horwell, UK) [27]. A vibra-
tion perception threshold (VPT) score ≥15 indicated peripher-
al neuropathy [28]. The study was not powered to assess
changes in these complications post-transplant.
Anthropometric measurements Participants were weighed to
the nearest 0.1 kg (SECA 959 electronic chair scales, SECA,
Birmingham, UK). Height, waist (between the lower margin
of the last palpable rib and the top of iliac crest [29]), hip
circumference (mid-trochanter), left mid-arm and left mid-
thigh circumference were recorded to the nearest 0.5 cm.
Body fat was estimated by air displacement plethysmography
(BOD POD; COSMED USA, Concord, CA, USA).
Mixed-meal tolerance tests with blood sampling Venous
blood samples were collected after an 8–10 h overnight fast
at 09:00 h. Participants adjusted their insulin therapy as de-
scribed [30] and a mixed meal of Ensure HP (Abbott, Maid-
enhead, UK) was administered; sampling was carried out
at −15, 0, 30, 60, 90, 120 and 180 min and plasma stored
at −80°C. Fasting samples were taken for the measure-
ment of glucose, C-peptide, HbA1c, full lipid profile
(total and HDL-cholesterol and triacylglycerol), full
blood count, liver function tests and antibodies, and
stimulated samples for the measurement of glucose and
C-peptide. A 90 min C-peptide level >50 pmol/l was
evidence of graft function [17].
Laboratory analyses
Glucose and C-peptide concentrations (Perkin Elmer
AutoDELFIA,Wokingham, UK until December 2011 and Sie-
mens Immulite 2000, Erlangen, Germany thereafter) were
analysed in a centralised laboratory [17]. HLA testing and
all other assays were done at the accredited laboratories at
the Royal Infirmary of Edinburgh. Concentrations of
haemoglobin, alanine transaminase, alkaline phosphatase, bil-
irubin, creatinine and urea, total cholesterol, HDL-cholesterol
and triacylglycerol were measured in automated analysers
(Haemoglobin: XE-5000, Sysmex Co, Kobe, Japan; others:
Architect 1600, Abbott Diagnostics, Maidenhead UK) [17].
LDL-cholesterol concentrations [17] and estimated GFR were
calculated and white cell and lymphocyte counts were
determined using flow cytometry (XE-5000, Sysmex,
Kobe, Japan). Inter- and intra-assay coefficients of var-
iability were all <10%.
Statistical analyses
Beta scores were calculated from HbA1c, insulin dose and
C-peptide concentrations during the mixed-meal tolerance test
(MMTT) [30] . The propor t ion of t ime spent in
hyperglycaemia, euglycaemia and hypoglycaemia was com-
puted from the CGMS data. Data are reported as median
(IQR). Differences between referred and transplanted partici-
pants were compared using Fisher’s exact test. A comparison
of proportions statistical approach was used to compare na-
tional data (socioeconomic status, employment and driving
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statistics) with the corresponding data in the referred and
transplanted participants and accounted for sample size. Mul-
tiple linear regression analysis with the independent variables
socioeconomic status, participant age, duration of diabetes
and presence of insulin pump therapy was performed on the
referral population to examine independent associations with
islet transplantation.
In the 14 participants who had data up to and including
12 months after first transplant, one-way repeated ANOVA
analyses were used with post hoc testing to compare pre-
transplant data with outcome data at approximately 1, 3, 6
and 12 months post-transplant. Statistical analyses were per-
formed in Stata 12 (Stata Corporation, College Station, TX,
USA). A p value <0.05 was considered to indicate statistical
significance.
Ethics approval
Participants provided written informed consent and the study
was approved by Lothian Research Ethics Committee, UK
and conducted in accordance with the principles endorsed by
the Declaration of Helsinki.
Results
Referred participants
One hundred and six participants were referred for assessment
(57%women) for islet transplantation through our programme
in Scotland. The median (IQR) characteristics of the partici-
pants were as follows: age 46 (37–53) years, weight 73.3
(63.6–85.0) kg, BMI 25.8 (23.1–29.9) kg/m2, insulin dose
0.55 (0.42–0.64) units/kg, HbA1c 8.2% (7.2–9.1%) (66 [55–
76] mmol/mol); forty-one per cent were on insulin pump ther-
apy. Sixty-two per cent of referred participants were in lower
socioeconomic groups compared with 50% in the gen-
eral population (p=0.01). The frequency distribution of
participants referred for islet transplantation within each
DEPCAT score is shown alongside the national data for
Scotland in Fig. 1 [19]. Sixty per cent of participants
were not employed or had a reduced ability to work,
significantly greater than the national figure of 6% reg-
istered unable to work due to ill health (p<0.01) [20].
Fifty-eight per cent of participants did not hold a
driver’s license, significantly greater than the national
figure of 32% (p<0.01) [23].
On multiple linear regression analysis, insulin pump thera-
py was the only factor associated with being listed for islet
transplantation (p<0.05). Referrals for transplantation includ-
ing exclusions are shown in electronic supplementary material
(ESM) Fig. 1.
Transplanted participants
Eighteen participants all with type 1 diabetes received 32
transplants. Two participants with previous renal transplants
were excluded from analyses. Therefore, data on 16 partici-
pants (9 women) who received 30 transplants (14 participants
with two transplants each; two participants with one transplant
each) and who were ≥3 months post-transplant are presented
(ESM Fig. 1). Fourteen participants (13 participants with two
transplants each; one participant with one transplant) were
≥12 months after the first transplant and sequential outcomes
for these participants are also presented. One participant had
polyglandular autoimmune disorder and was receiving phys-
iological hormone replacement with hydrocortisone. The me-
dian time to second transplant was 3.5 (2.3–4.9) months.
Compared with the general population in Scotland and the
referrals, there was a greater prevalence of socioeconomic dep-
rivation in participants who received transplants (73% socially
deprived; p<0.05; Fig. 1). In comparison with the referred
participants, participants who received transplants demonstrat-
ed a decreased ability to work (94%; p<0.01) and drive (88%;
p<0.0001). Participants who received transplants were more
likely to be on an insulin pump than on a basal-bolus insulin
regimen (69%; p<0.05). Baseline data for the transplant recip-
ients are shown (Table 1). Of note, these participants pre-
transplant had a high rate of hypoglycaemia with severe IAH
as reflected by Gold and Clarke scores (both pre-transplant 7
[5–7]; Table 2) and HbA1c levels at assessment were not nota-
bly high (7.9% [7.2–8.5%]; 63 [55–69] mmol/mol; Table 2).
Participants were mainly overweight or obese at assessment
(five were obese [BMI ≥30 kg/m2], six overweight [BMI
>25<30 kg/m2] and five had a normal BMI [BMI >20<
25 kg/m2]) and all participants were of white ethnicity; all
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Fig. 1 Frequency distribution of DEPCAT scores for participants. Fre-
quency distribution (%) of the general population in Scotland (n=5.06
million; black bars), participants referred for transplant assessment
(n=106; grey bars) and participants receiving transplants (n=18; white
bars) within each DEPCAT score. p<0.05 for general population vs all
groups and referrals vs transplant recipients. Frequency of severe
hypoglycaemia is greater in participants with DEPCAT scores ≥4
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had a history of diabetic retinopathy and the majority had pe-
ripheral neuropathy and autonomic neuropathy.
Donor data
All except one donor pancreas was processed by the Scottish
Islet Isolation Laboratory. Detailed donor data are shown in
ESM Table 1. IEQs transplanted were 9,355 (7,695–10,741)
IEQ/kg, with high purity 84 (76–89)% and viability 94
(91–96)%. Donor pancreases used were predominantly DBD
(83%) with longer cold ischaemia times (9.5 [8.5–10.0] h) than
those of DCD donors (8.0 [6.5–8.2] h; p<0.01). Thirteen of the
donors were obese, 11 overweight and six had normal BMI.
Transplant outcomes
Metabolic control, awareness of hypoglycaemia, diabetes-
related complications and lifestyle measures Islet
transplantation resulted in significant graft function post-
transplantation as reflected by the stimulated C-peptide con-
centrations that were maintained over the 1 year period
(Table 2). Transplantation resulted in significantly reduced
episodes of hypoglycaemia and improved awareness of
hypoglycaemia, with a reduction in insulin requirements and
an improved beta score of ≥3 at all assessment time points
post-transplantation over the 1 year period (Table 2). Im-
proved glycaemic control as reflected by the HbA1c level
was apparent at ~3 and ~6 months after the first transplant
and was concordant with the CGMS profiles, which showed
significantly diminished hypoglycaemia and hyperglycaemia
at ~3 and ~6 months post-transplant (p<0.01; Fig. 2). The
participant who developed graft failure (ESM Table 1) dem-
onstrated improved metabolic control at 12 months post-
transplant vs pre-transplant: time spent in hypoglycaemia
(measured by CGMS) was <2% vs 7%; HbA1c level was
7% (53 mmol/mol) vs 7.4% (57 mmol/mol); and the frequen-
cy of severe hypoglycaemia was diminished with no recorded
episodes 12 months post-transplant vs four episodes per week
pre-transplant. Ten of the 14 participants had achieved insulin
independence (with plasma glucose levels <10 mmol/l pre-
and post-meal) for a range of 1–12 months by 1 year. There
was no progression of diabetic retinopathy and one individual
demonstrated improvement in their background diabetic reti-
nopathy, and there was no evidence of progression of auto-
nomic neuropathy. There was a nonsignificant decrease in
VPT at 12 months post-transplant: 15 (5–16) vs 11 (4–15)
volts (p=0.10).
Of the 12 participants who had previously failed to renew
their driver’s license secondary to hypoglycaemia, four went
on to regain their license following assessments by the DVLA.
Five of the 14 participants who were working part time were
able to increase their work commitments by 100 (63–200)%
post-transplantation, resulting in an average increase in in-
come of 80%.
Immunological, haematological and biochemical indices Of
the 30 transplants analysed, matching for HLA-A, -B and -DR
was as follows: 1 mismatch (MM), n=1; 2 MM, n=2; 3 MM,
n=4; 4 MM, n=13; 5 MM, n=6; and 6 MM, n=4. In first
transplant cases, 11 of 16 were negative for HLA class I and
class II IgG antibodies (LABScreen, One Lambda (One
Lambda, Canoga Park, CA, USA)), four were positive for
nondonor-specific class I and/or class II antibodies and in
one case weak donor-specific class I antibodies were present.
For second transplant cases, eight of 14 were negative for
HLA class I and class II IgG antibodies (LABScreen, One
Lambda) and six were positive for nondonor-specific class I
and/or class II antibodies.
Three participants had increases in donor-specific HLA
antibodies after their first transplant, indicative of an active
immune response against the graft. In two cases these HLA
Table 1 Characteristics of all transplant participants at assessment
Assessment All participants
(n=16)
Participants with data
at 1 year (n=14)
Age at first transplant (years) 40 (35–53) 40 (34–52)
Duration of diabetes (years) 31 (27–40) 31 (24–40)
Sex (M:F) 7:9 6:8
White ethnicity (%) 100 100
Smokers % 12.5 14
Socially depriveda (%) 73 64
Inability or reduced ability to
workb (%)
94 93
Not driving secondary to
diabetes (%)
88 86
Insulin pump therapy (%) 69 71
Episodes of hypoglycaemia
per week
9 (4–10) 10 (4–11)
IAH (Gold score ≥4) (%) 94 93
IAH (Clarke score ≥4) (%) 94 93
Autonomic neuropathy (%) 69 64
Diabetic retinopathy
(all grades) (%)
100 100
Peripheral neuropathy (%) 75 79
The characteristics of all transplant participants (n=16) and of those with
follow-up data for a 1 year period (n=14) are expressed as median (IQR)
or percentages, as appropriate
The percentage of participants with IAH were scored by two independent
scoring systems (Gold and Clarke scores). Complications from previous
diabetes-related retinopathy were ascertained from case notes and retinal
eye screening reports, autonomic neuropathy was ascertained from case
notes, the clinical history and radiological examinations, and peripheral
neuropathy from the case notes including neurophysiological studies and
from neuroesthesiometer studies
a Patients with DEPCAT scores 4–7 were classed as socially deprived
b In all cases, inability or reduced ability to work was secondary to
diabetes
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antibodies were present at a low level pre-transplant and fol-
lowing the initial rise they returned to pre-transplant levels by
3 months post-transplant. In all three cases, the rise in HLA
donor-specific antibodies did not coincide with any loss of
graft function. In one of the three participants there was graft
failure as outlined in the complications section.
Post-transplant there was a fall in haemoglobin levels at
each assessment time point including at 12 months
(p<0.001); there was an initial fall in white cell count and
lymphocyte count (p<0.001) but these had both recovered
by 12 months; no change in platelet count was observed.
There was a trend for estimated GFR to decrease post-
transplant (p=0.06), and serum creatinine increased signifi-
cantly and remained elevated at each assessment (baseline to
12 months: 72 (64–83) to 93 (81–106) μmol/l, respectively;
p<0.001), although this was of no clinical consequence. No
change in lipid concentrations (total cholesterol, HDL-
cholesterol and calculated LDL-cholesterol and triacylglycer-
ol) and liver function tests (alkaline phosphatase, alanine
transaminase and bilirubin concentrations) were recorded dur-
ing follow-up.
Anthropometric changes Pre-transplant, nine of the 14 partic-
ipants were obese or overweight with a median BMI of
26.7 kg/m2 (Table 3). A reduction in weight, percentage fat
mass and arm circumference was seen by 6 months and was
still evident at 12 months post-transplant. Waist and hip cir-
cumference decreased significantly by 12 months post-trans-
plant. Energy intake to prevent severe hypoglycaemia was
reduced at each assessment period post-transplant, although
total energy intake was not significantly reduced (Table 3).
Complications One participant who received two islet trans-
plants separated by 2 months had complete graft failure
(C-peptide level <50 pmol/l) 4 months after their first trans-
plant. In this patient, de novo transient HLA antibodies direct-
ed at an HLA mismatch from the first islet graft were
detected previously but they were not coincident with
graft failure. One participant developed tinnitus on ta-
crolimus, and sirolimus was substituted. One participant
developed gastritis, and one developed neutropenia sec-
ondary to the immunosuppression and required a single
course of growth colony stimulating factor. There were
no surgical complications and no cases of carcinoma in
the short time of follow-up in this programme.
Table 2 Hypoglycaemia and metabolic assessments of transplant participants over a 1 year period
Metabolic assessment Pre-transplantation ~1 month ~3 months ~6 months ~12 months p ANOVA
Episodes of hypoglycaemia per week 10 (4–11) 2 (0–3) 1 (0–3) 0 (0–2) 0 (0–2) <0.0001a,b,c,d
Gold scoree 7 (5–7) 4 (2–6) 3 (2–6) 2 (1–5) 1 (1–2) <0.0001b,c,d
HbA1c (%) 7.9 (7.2–8.5) 7.4 (6.8–7.6) 6.8 (6.2–7.5) 7.0 (6.5–7.2) 7.2 (6.8–7.5) 0.001
b,c
HbA1c (mmol/mol) 63 (55–69) 57 (51–60) 51 (44–58) 53 (48–55) 55 (51–58)
Insulin requirements (kg−1) 0.52 (0.44–0.57) 0.03 (0.00–0.35) 0.20 (0.08–0.40) 0.31 (0.10–0.49) 0.25 (0.10–0.41) 0.0002a,b,c,d
Beta score 0 4 (3–4) 4 (2–5) 4 (3–4) 3 (2–4) <0.0001a,b,c,d
90 min C-peptide (pmol/l) 0 (0–0) 438 (380–550) 697 (294–1,166) 700 (157–878) 667 (303–897) <0.0001a,b,c,d
Measurements were taken pre-transplant and at ~1, ~3, ~6 and ~12 months post-transplant; median (IQR) data for the 14 participants with data up to and
including ~12 months post-transplant are shown
One-way ANOVAwas performed and recorded with post hoc testing, comparing pre-transplant data with all other time points post-transplant
a Denotes significant difference between pre-transplant and ~1 month values
b Difference between pre-transplant and ~3 month values
c Difference between pre-transplant and ~6 month values
d Difference between pre-transplant and ~12 month values
e The Gold score was taken in participants who had experienced ≥1 episode of hypoglycaemia since their last assessment
Pre-transplant 1 month 3 months 6 months 12 months
0
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Fig. 2 CGMS recordings pre-transplant and at ~1, ~3, ~6 and~12months
post-transplant. CGMS recordings were carried out for 6 days prior to
MMTT assessments. Proportion of time spent in hypoglycaemia (plasma
glucose level <4 mmol/l) or hyperglycaemia (plasma glucose level
≥10 mmol/l) was reduced by ~3 and ~6 months post-transplant vs pre-
transplant, as assessed by one-way repeated ANOVA analyses with post
hoc testing (**p<0.01)
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Discussion
The results from our single, health-service funded centre in
Scotland confirms that islet transplantation significantly re-
duces severe hypoglycaemia [25] and exogenous insulin re-
quirements, and improves diabetes control (as reflected by the
HbA1c and CGMS profiles, with evidence of C-peptide secre-
tion) [17]. These findings are consistent with those from other
centres [10, 31–33] and previously published UK outcomes
[17]. Importantly for a nationally funded service, the results
show that the majority of participants both referred and receiv-
ing transplants were from lower socioeconomic groups than
the general population [19], with a diminished ability to work
and drive. Furthermore, patients receiving transplants were the
most severely affected of the referrals in terms of socioeco-
nomic, employment and driving status.
The prevalence of type 1 diabetes is not associated with
social class [34, 35], showing equal representation in all so-
cioeconomic groups. However, severe hypoglycaemia com-
plicating type 1 diabetes occurs most frequently in those of
lower socioeconomic status [15]. This study is the first to
show results related to socioeconomic status and suggests that
a programme funding by a health service drives referrals and
islet transplantations in patients with type 1 diabetes from such
groups. Living in Scotland is associated with socioeconomic
deprivation [16, 36], and there may be a greater degree of
socioeconomic deprivation in our participants than transplant
recipients in other centres in the UK [17], although further
analyses are required to confirm this. The age of recipients
and duration of diabetes was in line with that in other studies
[10, 37]. Although some of the participants who received
transplants were on basal-bolus insulin regimens, insulin
pump therapy was associated with being listed for islet trans-
plantation, perhaps reflecting a staged approach to diabetes
management in many patients.
Although not powered to examine quality of life measures,
employment, personal income and the ability to drive ap-
peared to improve following transplantation and >70% of par-
ticipants achieved insulin independence, consistent with the
findings of other studies [10]. Studies that have more formally
examined quality of life indices have found improvements
[38] and we await further prospective studies in this field.
Our transplant recipients were mainly overweight pre-
transplant and the weight loss post-transplant was consistent
with that in other observational studies with <18 months
follow-up [32, 37]. Unlike many studies, none of our partici-
pants were treated with glucagon-like peptide-1 receptor ago-
nists, which may confound the results as they have central
inhibitory effects on appetite [37]. We have extended previ-
ously published observations to show a decrease in central and
upper body fat as measured by gold standard techniques post-
transplant [37]. The aetiology of the post-transplant weight
loss is likely to be multifactorial, including increased energy
expenditure related to both increased activity and postprandial
thermogenesis secondary to endogenous insulin secretion, as
well as a central effect of immunosuppressive therapy on
Table 3 Anthropometric and food intake measurements for hypoglycaemia of transplant recipients over a 1 year period
Anthropometric and caloric
assessment
Pre-transplantation ~1 month ~3 months ~6 months ~12 months p ANOVA
Weight (kg) 74.0 (64.4–81.7) 73.9 (62.9–80.3) 74.5 (61.5–78.9) 72.9 (57.5–79.0) 70.1 (59.0–78.3) <0.0001c,d
BMI (kg/m2) 26.7 (23.5–29.8) 26.4 (23.6–29.3) 26.4 (23.7–28.7) 25.7 (21.1–28.2) 25.2 (21.3–26.6) <0.0001c,d
Fat mass (%) 31.4 (20.3–35.9) 29.3 (21.1–35.2) 27.8 (20.9–34.6) 25.8 (16.8–34.5) 23.5 (16.3–32.3) <0.0001c,d
Waist circumference (cm) 85.5 (78.5–95.0) 85.0 (79.5–95.2) 82.0 (79.5–94.0) 81.5 (75.0–92.0) 79.0 (76.0–94.0) 0.0004d
Hip circumference (cm) 95.0 (90.5–101.5) 97.0 (91.0–104.5) 94.5 (88.0–99.5) 94.0 (88.5–101.5) 90.0 (86.5–100.5) 0.01d
Left mid-arm circumference (cm) 30.0 (28.0–32.0) 30.0 (28.0–32.0) 30.0 (28.0–30.5) 29.5 (27.0–30.5) 29.0 (27.0–30.0) 0.001c,d
Left thigh circumference (cm) 53.0 (46.0–59.0) 52.0 (46.0–55.0) 52.0 (46.0–58.0) 51.0 (47.0–57.0) 50.0 (46.0–55.0) 0.37
kJ for hypoglycaemia (week−1) 4,665 (3,105–8,954) 456 (113–1,402) 573 (146–1,623) 0 (0–423) 0 (0–293) <0.0001a,b,c,d
Total kJ (day−1) 7,858 (7,510–9,318) 7,531 (7,355–8,029) 7,184 (6,184–8,134) 7,251 (6,205–7,820) 6,971 (5,912–7,707) 0.08
Anthropometric and dietetic measurements were taken pre-transplant and at ~1, ~3, ~6 and ~12 months post-transplant; median (IQR) data for the 14
participants with data up to and including ~12 months post-transplant are shown
One-way ANOVAwas performed with post hoc testing, comparing pre-transplant data with all other time points post-transplant
a Denotes significant difference between pre-transplant and ~1 month values
b Difference between pre-transplant and ~3 month values
c Difference between pre-transplant and ~6 month values
d Difference between pre-transplant and ~12 month values
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appetite. It is possible that participants may have
underestimated their energy intake using the food diaries and
more accurate assessments of energy intake would be useful
[39]. Our study is limited by the fact that the participants were
on differing quantities of exogenous insulin and it would be
more controlled to study transplant recipients that are insulin
independent to better understand the changes in energy bal-
ance post-transplantation.
Notably, no major complications have been demonstrated
and the changes in haematological indices and renal function
secondary to the immunosuppression have been previously
reported [32]. In contrast to other studies, we did not see a rise
in triacylglycerol concentrations post-transplant, perhaps be-
cause immunosuppression regimens differed.
The occurrence of donor-specific HLA antibodies in three
participants was transient in each case and not related to coin-
cident graft dysfunction or C-peptide response, although we
cannot comment on the impact that this has on long-term graft
survival [40].
The predominance of higher BMI donor pancreases isolat-
ed for islet transplantation reflects that the aims of the shared
vascularised pancreas and islet transplantation service have
been met. The second islet transplant was also given
~3 months from the first transplant in line with the goals of
the programme. Despite not achieving a target islet mass (IEQ
≥10,000/kg) in many of our patients, our short-term clinical
outcomes are comparable to those of other centres and reflect
the pragmatic approach that it has been necessary to adopt in
the face of an ongoing shortage of organ donors and an over-
weight recipient population. DCD donors, in common with
other programmes [10], were utilised to good effect. Although
no participant received islet transplants from two DCD donors
(precluding an analysis of DCD status alone), participants
receiving two islet transplants including one from a DCD
donor had equivalent stimulated C-peptide concentrations to
participants receiving islet transplants from DBD donors
alone. This finding is consistent with the observation that
islets fromDCD donors can be used effectively. The relatively
good C-peptide responses that have been attained may be due
to a relatively young donor age, although other factors may be
important. The advantage of assessing measures from a single
transplant and isolation centre is that participant assessments
and the isolation procedures are less prone to variability. Our
outcomes, with stimulated C-peptide readings reflecting a
functioning graft and stable glycaemic control as reflected
by the CGMS recordings with beta scores ≥3, are consistent
with the aims of the programme for predominantly abrogating
hypoglycaemia [41]. The deterioration in glycaemic control
>6 months post-transplant is in line with the outcomes from
other programmes [32].
In conclusion, the islet transplantation outcomes from our
single, nationally funded health centre in Scotland demon-
strate that referrals and transplantations are predominantly
from socioeconomically deprived groups with low employ-
ment and a decreased ability to drive secondary to their
hypoglycaemia. Islet transplantation reduced the frequency
of hypoglycaemia and improved awareness of hypoglycaemia
and glycaemic control. Transplantation also diminished insu-
lin requirements and decreased central obesity and fat mass.
Furthermore, there was evidence of endogenous insulin secre-
tion post-transplantation. Our studies indicate that quality of
life may be improved post-transplantation, as assessed by
driving status, an increased ability to work and increased per-
sonal income; however, further prospective studies are re-
quired to demonstrate long-term socioeconomic benefit.
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